- Ophthotech (OPHT) could potentially receive over $1B in milestone and other payments - including the $200M upfront free - during the course of its collaboration with Novartis (NVS) for the commercialization of Forvista, as well as any royalties on sales.
- Fovista is in a Phase III program consisting of three trials.
- Ophthotech's shares were +24% premarket. (PR)
at Nasdaq.com (Mon, 11:45AM)